| CAT # | Inoa Huahana | wehewehe |
| CPD100230 | JBJ-04-125-02 R-isomer | |
| CPD3232 | NTN21277 | ʻO NTN21277, i ʻike ʻia ʻo PROTAC 3 e pili ana iā Gefitinib he PROTAC-recruiting VHL e hoʻowalewale i ka hoʻohaʻahaʻa ʻana o EGFR a me EGFR mutants me DC50 o 11.7 nM a me 22.3 nM no HCC827 cell (Exon 19 del) a me H3255 cell (L858R). |
| CPDB3615 | Nazartinib; EGF816; NVS-816 | ʻO Nazartinib, ka mea i ʻike ʻia ʻo EGF816 a me NVS-816, he mea hiki ke hoʻololi ʻia, ke kolu o ka hanauna, mutant-selective epidermal growth factor receptor (EGFR) inhibitor, me ka hana antineoplastic. |
| CPDB0934 | EAI-045 | ʻO EAI045 he mea hoʻohana ikaika a koho EGFR. Kuhi ʻo EAI045 i nā mutants EGFR kūpaʻa i ka lāʻau akā mālama i ka ʻano ʻano ʻāhiu. EAI045 inhibits L858R/T790M-mutant EGFR me ka haʻahaʻa-nanomolar potency i biochemical assays. |
| CPDB0101 | Poziotinib | Ke hoʻokolokolo ʻia nei nā papa hana i loaʻa ka poziotinib i nā hoʻokolohua lapaʻau no ka mālama ʻana i ka EGFR-mutant lung adenocarcinoma. |
| CPDB0137 | Osimertinib Mesylate | ʻO Osimertinib, i kapa ʻia ʻo mereletinib a me AZD-9291, he kolu o ka hanauna EGFR inhibitor, i hōʻike i ka ʻōlelo hoʻohiki i nā haʻawina preclinical a hāʻawi i ka manaolana no nā poʻe maʻi me nā maʻi maʻi maʻi maʻi i kū i ke kūʻē i nā mea hoʻopaneʻe EGFR. |
